Tempest Therapeutics (NASDAQ: TPST) has appointed two independent directors, Drake Richey and John Yee, MD, MPH, to its board of directors (BoD), effective June 4, 2026.
Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to Tempest’s BoD.
Mr. Richey serves as president of Bush & Company, a financial advisory firm that advises high-net-worth families and business owners on investment strategy, risk management, and multi-generational planning. Dr. Yee is SVP, medical affairs, at closely held Apnimed.
In a statement, Matt Angel, PhD, president and CEO of Tempest, commented, “Over the past several months, we have built a portfolio of CAR-T cell therapy product candidates targeting safe, effective treatments for patients with advanced cancers. The addition of Drake and John to the board could further enable us to realize our vision of providing meaningful treatment options to cancer patients that have either failed or relapsed from prior therapies, while supporting Tempest’s focus on driving growth and disciplined capital allocation. I look forward to Drake’s and John’s insights as we continue to position the company for long-term success.”
